NEW YORK – Invitae today announced a $50 million deal to acquire Jungla, an artificial intelligence-driven biotech firm that it believes will enhance its variant interpretation capabilities.

Jungla has developed the cloud-based Functional Modeling Platform, which uses machine learning to integrate functional, structural, and computational data and create predictive models that can be used to interpret the clinical significance of genomic variants. Invitae sees this technology as complementary to its own variant classification and interpretation method, called Sherloc.